BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38450965)

  • 21. Hydroxychloroquine and risk of development of cancers: a nationwide population-based cohort study.
    Mao IC; Lin CY; Wu CL; Kor CT; Chang CC
    Ther Clin Risk Manag; 2018; 14():1435-1443. PubMed ID: 30154660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis.
    Liu Y; Zhang Y; Wei Y; Yang H
    Arch Gynecol Obstet; 2021 Feb; 303(2):435-441. PubMed ID: 32880707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.
    Liu JM; Yu CP; Chuang HC; Wu CT; Hsu RJ
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):475-482. PubMed ID: 30692587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
    Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxychloroquine in rheumatic autoimmune disorders and beyond.
    Nirk EL; Reggiori F; Mauthe M
    EMBO Mol Med; 2020 Aug; 12(8):e12476. PubMed ID: 32715647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study.
    Yen CY; Lee PH; Yen JC; Chen CC; Hu HY; Tseng PC
    Medicine (Baltimore); 2019 Apr; 98(14):e15122. PubMed ID: 30946384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.
    Hsu CY; Lin YS; Cheng TT; Syu YJ; Lin MS; Lin HF; Su YJ; Chen YC; Chen JF; Chen TH
    Rheumatology (Oxford); 2018 Oct; 57(10):1743-1751. PubMed ID: 29931367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
    Fessler BJ; Alarcón GS; McGwin G; Roseman J; Bastian HM; Friedman AW; Baethge BA; Vilá L; Reveille JD;
    Arthritis Rheum; 2005 May; 52(5):1473-80. PubMed ID: 15880829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
    Seo MR; Chae J; Kim YM; Cha HS; Choi SJ; Oh S; Roh CR
    Lupus; 2019 May; 28(6):722-730. PubMed ID: 30971164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
    Gupta A; Shields KJ; Manzi S; Wasko MC; Sharma TS
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):828-832. PubMed ID: 33098269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
    Walbi IA; Albarqi HA; Alghanim NS; Albadi MA; Al Maimouni HM; Alkahtani SA; Alshabi AM; Alali AS; Alqahtani F; Al-Najjar AH; Hazzazi MA; Alanazi DS; Sabei AA; Alsaweed OS; Alajra RK; Alqhtani H
    J Int Med Res; 2022 Apr; 50(4):3000605221090363. PubMed ID: 35387504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis.
    Liu Y; Wei Y; Zhang Y; Yang H
    Clin Rheumatol; 2023 May; 42(5):1223-1235. PubMed ID: 36729357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
    Leroux M; Desveaux C; Parcevaux M; Julliac B; Gouyon JB; Dallay D; Pellegrin JL; Boukerrou M; Blanco P; Lazaro E
    Lupus; 2015 Nov; 24(13):1384-91. PubMed ID: 26082465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
    Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
    Mavrikakis I; Sfikakis PP; Mavrikakis E; Rougas K; Nikolaou A; Kostopoulos C; Mavrikakis M
    Ophthalmology; 2003 Jul; 110(7):1321-6. PubMed ID: 12867385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
    Jorge A; McCormick N; Lu N; Zheng Y; Esdaile J; De Vera M; Choi H; Aviña-Zubieta JA
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1219-1223. PubMed ID: 32407570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.